Denali Therapeutics
DNLI
240 hedge funds and large institutions have $1.97B invested in Denali Therapeutics in 2025 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 90 increasing their positions, 67 reducing their positions, and 23 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
91% more call options, than puts
Call options by funds: $3M | Put options by funds: $1.57M
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
34% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 67
4% more funds holding
Funds holding: 230 → 240 (+10)
2% more capital invested
Capital invested by funds: $1.93B → $1.97B (+$42.4M)
2.04% less ownership
Funds ownership: 94.71% → 92.67% (-2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$39.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$34.4M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15.3M |
| 4 |
SC
Stempoint Capital
New York
|
+$14.8M |
| 5 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$80.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.2M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$11.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.88M |
DNLI Hedge Fund Activity: Q3 2025 in Review
240 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2025, worth a combined $1.97B — up 2.2% from $1.93B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new DNLI positions and 23 closed out — a net gain of 13 holders — while 90 added to existing stakes and 67 trimmed.
The largest buyer was Holocene Advisors, adding an estimated $39.3M. The largest seller was Wellington Management Group, cutting an estimated $80.5M.
- 240 institutional investors held Denali Therapeutics (DNLI) as of Q3 2025, up from 230 in Q2 2025.
- Funds reported $1.97B of Denali Therapeutics stock for Q3 2025, up 2.2% quarter-over-quarter.
- 36 funds opened new Denali Therapeutics positions in Q3 2025 and 23 closed out, a net change of +13 holders.
- The largest Denali Therapeutics buyer in Q3 2025 was Holocene Advisors, an estimated $39.3M added.
- The largest Denali Therapeutics seller in Q3 2025 was Wellington Management Group, an estimated $80.5M sold.
Based on aggregated 13F filings for Q3 2025.